Key Q1 2025 Highlights Cash Flow from Operating Activities and Adjusted Free Cash Flow, while down year-over-year, are significantly better in Q1 2025 versus Q1 2024 when adjusting for the positive impacts of the tax refund and contributions from divested assets in the prior year period. Additional Q1 2025 Performance Highlights Revenue and Adj. Revenue(1): $751M Pre-tax Income (Loss): $(56)M Adj. EBITDA Margin(1): 4.9% New Business Signings ACV(2): $109M Net ARR Activity Metric(2) (TTM): $116M FLORHAM PARK ...

Date: Wednesday, May 14, 2025 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Webcast Link: https://events.q4inc.com/attendee/137642555 Media and Investor Relations Contact: Jennifer Wu ir@belitebio.com Webcast Link Instructions You can join the live webcast by visiting the link above or the "Presentations & Events" section of the Company's Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event. Ab ...

Core Viewpoint - PDS Biotechnology Corporation is set to report its financial results for Q1 2025 and provide updates on its clinical programs during a conference call on May 14, 2025 [1][2]. Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on enhancing the immune system's ability to target and eliminate cancers [3]. - The company has initiated a pivotal clinical trial for its lead program, which targets advanced HPV16-positive head and neck squamous cell cancers [3]. - The lead investigational targeted immunotherapy, Versamune HPV, is being developed in combination with a standard immune checkpoint inhibitor and in a triple combination with PDS01ADC, an IL-12 fused antibody drug conjugate [3].

Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH (VP-102) is also being developed to address common warts, which represent a significant unmet need in medical dermatology [3] - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Upcoming Events - The company will host a conference call and live webcast on May 13, 2025, at 4:30 p.m. ET to discuss its financial results for Q1 2025 and provide a corporate update [1] - Participants can join the call via telephone or through a live audio webcast available on the company's investor relations website [2]

Core Insights - Barinthus Biotherapeutics plc focuses on developing therapies for immunological and inflammatory diseases, with a strategic emphasis on its lead asset, VTP-1000, for celiac disease [2][3] - The company is on track to announce Phase 1 single ascending dose data for VTP-1000 in Q3 2025 and will initiate the multiple ascending dose part of the trial in the second half of 2025 [2][12] - Recent data from Phase 2 trials of VTP-300 for chronic hepatitis B (CHB) show promising results, supporting its potential as a functional cure [3][4][5] Clinical Developments - Data from two Phase 2 trials of VTP-300 will be presented at the EASL Congress 2025, showcasing significant findings from the HBV003 and IM-PROVE II studies [3][4] - The HBV003 study indicated that 33% of participants with HBsAg levels ≤200 IU/mL achieved ≥1 log decline in HBsAg by Day 169 [6] - The IM-PROVE II study demonstrated that 25% of participants receiving a combination therapy achieved functional cure [11] Financial Highlights - For Q1 2025, the company reported a net loss of $19.6 million, or $(0.49) per share, compared to a net loss of $15.5 million, or $(0.40) per share in Q1 2024 [18][22] - Research and development expenses decreased to $8.3 million in Q1 2025 from $11.1 million in Q1 2024, attributed to reduced preclinical activity and workforce [13][22] - As of March 31, 2025, the company had cash and cash equivalents of $100.6 million, expected to fund operations into 2027 [13][20] Corporate Updates - In January 2025, Barinthus Bio announced a strategic refocus on immunology and inflammation, planning to seek partners for VTP-300 after the completion of the ongoing Phase 2b trial [7] - The company aims to leverage its differentiated capabilities in achieving sustained HBsAg loss and functional cure in CHB patients [7] - Upcoming milestones include topline results from the Phase 1 PCA001 trial for prostate cancer (VTP-850) [8]

SOUTHLAKE, Texas, May 7, 2025 /PRNewswire/ -- Sabre Corporation ("Sabre") (NASDAQ: SABR) today announced financial results for the quarter ended March 31, 2025. Sabre has posted its first quarter 2025 earnings release and earnings presentation to its Investor Relations webpage at investors.sabre.com/financial-information/quarterly results. The earnings release is also available on the Securities and Exchange Commission's website at www.sec.gov.As previously announced, Sabre will host a live webcast of its f ...

First quarter 2025 GAAP net income of $3.1 million or $0.27 per basic weighted average common share and Distributable Earnings(1) of $3.5 million or $0.31 per basic weighted average common shareWEST PALM BEACH, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Sunrise Realty Trust, Inc. (NASDAQ:SUNS) (“SUNS” or the “Company”) today announced its results for the quarter ended March 31, 2025. SUNS reported generally accepted accounting principles (“GAAP”) net income of $3.1 million or $0.27 per basic weighted average co ...

Core Insights - Verisk reported strong financial results for Q1 2025, with a revenue increase of 7.0% year-over-year, reaching $753 million, and organic constant currency revenue growth of 7.9% [5][8][16] - The company achieved a net income of $232 million, reflecting a 5.9% increase compared to the previous year, and an adjusted EBITDA of $417 million, up 9.5% [3][10][17] - Verisk returned over $250 million to shareholders through dividends and share repurchases, demonstrating confidence in its business model and financial strength [3][23] Financial Performance - Revenues for Q1 2025 were $753 million, up from $704 million in Q1 2024, marking a 7.0% increase [5][8] - Net income increased to $232 million from $219 million, a rise of 5.9% [10][40] - Adjusted EBITDA reached $417 million, up 9.5% from $380 million in the same quarter last year [10][11] - Diluted EPS attributable to Verisk was $1.65, an increase of 8.6% from $1.52 [13][40] - Free cash flow grew by 23.3% to $391 million, compared to $317 million in Q1 2024 [15][56] Segment Performance - Underwriting revenues increased by 6.8% to $532 million, with organic constant currency growth of 7.2% [7][16] - Claims revenues grew by 7.5% to $221 million, with organic constant currency growth of 9.6% [7][16] Shareholder Returns - The company returned over $250 million to shareholders through dividends and share repurchases [3][23] - The dividend per share was increased to $0.45, up 15.4% from $0.39 [5][15] 2025 Financial Guidance - Verisk reiterated its financial guidance for 2025, projecting total revenue between $3.03 billion and $3.08 billion, and adjusted EBITDA between $1.67 billion and $1.72 billion [18]

Core Insights - Vishay Intertechnology, Inc. reported its fiscal first quarter results for the period ending March 29, 2025, highlighting a revenue of $715.2 million and a gross margin of 19.0% [1][9] - The company anticipates a sequential revenue increase of 6% for the second quarter of 2025, with expected revenues in the range of $760 million +/- $20 million [3][4] Financial Performance - The first quarter of 2025 saw a net loss attributable to Vishay stockholders of $4.1 million, translating to a loss per share of $0.03 [9][14] - The gross profit for the first quarter was $135.6 million, with a gross margin decrease from 19.9% in the previous quarter [9][14] - The book-to-bill ratio was reported at 1.08, with semiconductors at 1.12 and passive components at 1.04 [9] Operational Highlights - The company noted that channel inventory has normalized, which is expected to support revenue growth and profitability [3] - Vishay's backlog at the end of the quarter was approximately 4.7 months [9] Outlook - Management's guidance for the second quarter includes a gross profit margin range of 19.0% +/- 50 basis points, accounting for the negative impact of tariffs [4] - The anticipated effects of evolving tariff policies and demand uncertainties are being closely monitored [3] Cash Flow and Investments - Net cash provided by operating activities for the first quarter was $16.1 million, a decrease from $80.2 million in the same period last year [18] - Free cash flow for the first quarter was reported at $(45.2) million, compared to $27.9 million in the prior year [20] Balance Sheet - As of March 29, 2025, total assets were $4.2 billion, an increase from $4.1 billion at the end of the previous year [15][17] - Current liabilities totaled $705.4 million, with long-term debt less current portion at $988.2 million [17]

SHANGHAI, China, May 07, 2025 (GLOBE NEWSWIRE) -- GDS Holdings Limited ("GDS Holdings", "GDS" or the "Company") (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high- performance data centers in China, today announced that it will report its first quarter 2025 unaudited financial results after the close of the Hong Kong market and before the open of the U.S. market on May 20, 2025. About GDS Holdings Limited GDS Holdings Limited (NASDAQ: GDS; HKEX: 9698) is a leading developer and operator of ...